2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

and non-small cell lung carcinoma.

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

1

Peptides

1

Inhibitory Antibodies

3

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N6252
    Gypenoside XLVI
    1 Publications Verification

    		 Others Cancer
    Gypenoside XLVI is one of the major dammarane-type triterpenoid saponins from Gynostamma pentaphallum . Gypenoside XLVI has a tetracyclic triterpene structure and possess potent non-small cell lung carcinoma A549 cell inhibitory activity .
    Gypenoside XLVI
  • HY-P99052
    Tislelizumab
    2 Publications Verification

    		 PD-1/PD-L1 Inflammation/Immunology Cancer
    Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma .
    Tislelizumab
  • HY-10261
    Afatinib
    Maximum Cited Publications
    68 Publications Verification

    BIBW 2992

    		 EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK Cancer
    Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR wt, EGFR L858R, EGFR L858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .
    Afatinib
  • HY-10261A
    Afatinib dimaleate
    Maximum Cited Publications
    68 Publications Verification

    BIBW 2992MA2

    		 EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK Cancer
    Afatinib (BIBW 2992) dimaleate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR wt, EGFR L858R, EGFR L858R/T790M and HER2, respectively. Afatinib dimaleate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .
    Afatinib dimaleate
  • HY-169579
    PLK1-IN-11

    		Polo-like Kinase (PLK) Cancer
    PLK1-IN-11 (Cluster 4, 16953209) is a PLK1 inhibitor, with IC50 of 1 μM. PLK1-IN-11 can be used in research on a variety of cancers, including pancreatic, ovarian, breast, and non-small cell lung carcinoma .
    PLK1-IN-11
  • HY-169741
    DDR1-IN-10

    		Discoidin Domain Receptor Cancer
    DDR1-IN-10 (compound 7q) is a DDR1 inhibitor. DDR1-IN-10 can be used in the study of pancreatic cancer, non-small cell lung cancer, and gastric carcinoma .
    DDR1-IN-10
  • HY-148260
    KRAS G12D inhibitor 16

    		Ras Cancer
    KRAS G12D inhibitor 16 is a KRAS G12D inhibitor. KRAS G12D inhibitor 16 has inhibitory activity against KRAS G12D and KRAS G12D mutation with IC50 value of 0.7 nM and 0.35 μM, respectively. KRAS G12D inhibitor 16 can be used for the research of many malignant tumor, such as pancreatic ductal adenocarcinomas (PDAC), colon and rectal carcinomas (CRC), non-small cell lung carcinomas (NSCLC) .
    KRAS G12D inhibitor 16
  • HY-10261D
    Afatinib oxalate

    BIBW 2992 oxalate

    		 EGFR Autophagy Apoptosis c-Met/HGFR Akt Cancer
    Afatinib (BIBW 2992) oxalate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR wt, EGFR L858R, EGFR L858R/T790M and HER2, respectively. Afatinib oxalate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .
    Afatinib oxalate
  • HY-P10762
    CBP-1008

    		Peptide-Drug Conjugates (PDCs) Folate Receptor (FR) TRP Channel Cancer
    CBP-1008 is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. CBP-1008 binds to FRα with high affinity and TRPV6 with low affinity. CBP-1008 has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .
    CBP-1008
  • HY-10261R
    Afatinib (Standard)

    		EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK Cancer
    Afatinib (Standard) is the analytical standard of Afatinib. This product is intended for research and analytical applications. Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .
    Afatinib (Standard)
  • HY-W403933R
    12-Ketochenodeoxycholic acid (Standard)

    		Autophagy Metabolic Disease
    Afatinib (Standard) is the analytical standard of Afatinib. This product is intended for research and analytical applications. Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .
    12-Ketochenodeoxycholic acid (Standard)
  • HY-10261AR
    Afatinib (dimaleate) (Standard)

    		EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK Cancer
    Afatinib (dimaleate) (Standard) is the analytical standard of Afatinib (dimaleate). This product is intended for research and analytical applications. Afatinib (BIBW 2992) dimaleate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib dimaleate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .
    Afatinib (dimaleate) (Standard)
  • HY-W012241R
    Dodecanedioic acid (Standard)

    		Endogenous Metabolite Others
    Afatinib (dimaleate) (Standard) is the analytical standard of Afatinib (dimaleate). This product is intended for research and analytical applications. Afatinib (BIBW 2992) dimaleate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib dimaleate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .
    Dodecanedioic acid (Standard)
  • HY-10261E
    (R)-Afatinib

    (R)-BIBW 2992

    		 EGFR c-Met/HGFR p38 MAPK Cancer
    (R)-Afatinib ((R)-BIBW 2992) is the Afatinib isomer. Afatinib (HY-10261) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR wt, EGFR L858R, EGFR L858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .
    (R)-Afatinib
  • HY-110088
    SCH529074
    1 Publications Verification

    		 MDM-2/p53 Cancer
    SCH529074 is a potent and orally active p53 activator. SCH529074 binds specifically and conformation-dependently to p53 DBD ( DNA binding domain) with a Ki of 1-2 μM in a saturable manner. SCH529074 restores mutant p53 function and interrupts HDM2-mediated ubiquitination of wild Type p53. SCH529074 can be used for the study of non-small-cell lung carcinoma (NSCLC) .
    SCH529074
  • HY-153863
    MS934

    		PROTACs MEK Raf Cancer
    MS934 is a novel improved VHL-recruiting MEK 1/2 PROTAC degrader. MS934 also degrades CRAF. MS934 can be used for the research of variety of human cancers, such as melanoma, nonsmall cell lung cancer (NSCLC), colorectal cancer, primary brain tumors, and hepatocellular carcinoma (Pink: Target protein ligand (HY-168288); Black: linker (HY-168289); Blue: E3 ligase ligand (HY-112078)) .
    MS934

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: